Literature DB >> 23000621

The distribution of phosphodiesterase 2A in the rat brain.

D T Stephenson1, T M Coskran, M P Kelly, R J Kleiman, D Morton, S M O'Neill, C J Schmidt, R J Weinberg, F S Menniti.   

Abstract

The phosphodiesterases (PDEs) are a superfamily of enzymes that regulate spatio-temporal signaling by the intracellular second messengers cAMP and cGMP. PDE2A is expressed at high levels in the mammalian brain. To advance our understanding of the role of this enzyme in regulation of neuronal signaling, we here describe the distribution of PDE2A in the rat brain. PDE2A mRNA was prominently expressed in glutamatergic pyramidal cells in cortex, and in pyramidal and dentate granule cells in the hippocampus. Protein concentrated in the axons and nerve terminals of these neurons; staining was markedly weaker in the cell bodies and proximal dendrites. In addition, in both hippocampus and cortex, small populations of non-pyramidal cells, presumed to be interneurons, were strongly immunoreactive. PDE2A mRNA was expressed in medium spiny neurons in neostriatum. Little immunoreactivity was observed in cell bodies, whereas dense immunoreactivity was found in the axon tracts of these neurons and their terminal regions in globus pallidus and substantia nigra pars reticulata. Immunostaining was dense in the medial habenula, but weak in other diencephalic regions. In midbrain and hindbrain, immunostaining was restricted to discrete regions of the neuropil or clusters of cell bodies. These results suggest that PDE2A may modulate cortical, hippocampal and striatal networks at several levels. Preferential distribution of PDE2A into axons and terminals of the principal neurons suggests roles in regulation of axonal excitability or transmitter release. The enzyme is also in forebrain interneurons, and in mid- and hindbrain neurons that may modulate forebrain networks and circuits.
Copyright © 2012 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23000621      PMCID: PMC4409981          DOI: 10.1016/j.neuroscience.2012.09.011

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  36 in total

1.  mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain.

Authors:  Wilma C G Van Staveren; Harry W M Steinbusch; Marjanne Markerink-Van Ittersum; David R Repaske; Michael F Goy; Jun Kotera; Kenji Omori; Joseph A Beavo; Jan De Vente
Journal:  J Comp Neurol       Date:  2003-12-22       Impact factor: 3.215

Review 2.  Interneurons of the neocortical inhibitory system.

Authors:  Henry Markram; Maria Toledo-Rodriguez; Yun Wang; Anirudh Gupta; Gilad Silberberg; Caizhi Wu
Journal:  Nat Rev Neurosci       Date:  2004-10       Impact factor: 34.870

Review 3.  Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs).

Authors:  D M Juilfs; S Soderling; F Burns; J A Beavo
Journal:  Rev Physiol Biochem Pharmacol       Date:  1999       Impact factor: 5.545

4.  Axon arbors and synaptic connections of hippocampal mossy cells in the rat in vivo.

Authors:  P S Buckmaster; H J Wenzel; D D Kunkel; P A Schwartzkroin
Journal:  J Comp Neurol       Date:  1996-03-04       Impact factor: 3.215

5.  Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes.

Authors:  Michele P Kelly; Sheree F Logue; Julie Brennan; Jonathon P Day; Subha Lakkaraju; Lixin Jiang; Xiaotian Zhong; May Tam; Stacey J Sukoff Rizzo; Brian J Platt; Jason M Dwyer; Sarah Neal; Virginia L Pulito; Michael J Agostino; Steven M Grauer; Rachel L Navarra; Cody Kelley; Thomas A Comery; Richard J Murrills; Miles D Houslay; Nicholas J Brandon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

6.  Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues.

Authors:  Viktor Lakics; Eric H Karran; Frank G Boess
Journal:  Neuropharmacology       Date:  2010-05-21       Impact factor: 5.250

7.  Efferent connections of the habenular nuclei in the rat.

Authors:  M Herkenham; W J Nauta
Journal:  J Comp Neurol       Date:  1979-09-01       Impact factor: 3.215

8.  Dual acylation of PDE2A splice variant 3: targeting to synaptic membranes.

Authors:  Corina Russwurm; Georg Zoidl; Doris Koesling; Michael Russwurm
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

9.  A novel cyclic GMP stimulated phosphodiesterase from rat brain.

Authors:  Q Yang; M Paskind; G Bolger; W J Thompson; D R Repaske; L S Cutler; P M Epstein
Journal:  Biochem Biophys Res Commun       Date:  1994-12-30       Impact factor: 3.575

Review 10.  Intracellular targeting of phosphodiesterase-4 underpins compartmentalized cAMP signaling.

Authors:  Martin J Lynch; Elaine V Hill; Miles D Houslay
Journal:  Curr Top Dev Biol       Date:  2006       Impact factor: 4.897

View more
  17 in total

1.  First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430.

Authors:  Mika Naganawa; Rikki N Waterhouse; Nabeel Nabulsi; Shu-Fei Lin; David Labaree; Jim Ropchan; Sanela Tarabar; Nicholas DeMartinis; Adam Ogden; Anindita Banerjee; Yiyun Huang; Richard E Carson
Journal:  J Nucl Med       Date:  2016-04-21       Impact factor: 10.057

Review 2.  Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?

Authors:  Dominic Ngima Nthenge-Ngumbau; Kochupurackal P Mohanakumar
Journal:  Mol Neurobiol       Date:  2017-01-06       Impact factor: 5.590

3.  Cross-regulation of Phosphodiesterase 1 and Phosphodiesterase 2 Activities Controls Dopamine-mediated Striatal α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Trafficking.

Authors:  Roy S Song; Rosa Tolentino; Eric A Sobie; Susana R Neves-Zaph
Journal:  J Biol Chem       Date:  2016-09-07       Impact factor: 5.157

4.  Selective phosphodiesterase-2A inhibitor alleviates radicular inflammation and mechanical allodynia in non-compressive lumbar disc herniation rats.

Authors:  Jun-Nan Wang; Xue-Jun Zhao; Zhi-Hua Liu; Xu-Li Zhao; Tao Sun; Zhi-Jian Fu
Journal:  Eur Spine J       Date:  2017-03-10       Impact factor: 3.134

5.  In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.

Authors:  John P Redrobe; Morten Jørgensen; Claus T Christoffersen; Liliana P Montezinho; Jesper F Bastlund; Martin Carnerup; Christoffer Bundgaard; Linda Lerdrup; Niels Plath
Journal:  Psychopharmacology (Berl)       Date:  2014-03-01       Impact factor: 4.530

6.  Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition.

Authors:  Sarah Threlfell; Anthony R West
Journal:  Basal Ganglia       Date:  2013-12-01

7.  Phosphodiesterases PDE2A and PDE10A both change mRNA expression in the human brain with age, but only PDE2A changes in a region-specific manner with psychiatric disease.

Authors:  Reagan Farmer; Steven D Burbano; Neema S Patel; Angelo Sarmiento; Abigail J Smith; Michy P Kelly
Journal:  Cell Signal       Date:  2020-02-29       Impact factor: 4.315

8.  The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease.

Authors:  Joanna Schwenkgrub; Malgorzata Zaremba; Ilona Joniec-Maciejak; Agnieszka Cudna; Dagmara Mirowska-Guzel; Iwona Kurkowska-Jastrzębska
Journal:  PLoS One       Date:  2017-07-28       Impact factor: 3.240

9.  PDE11A negatively regulates lithium responsivity.

Authors:  G Pathak; M J Agostino; K Bishara; W R Capell; J L Fisher; S Hegde; B A Ibrahim; K Pilarzyk; C Sabin; T Tuczkewycz; S Wilson; M P Kelly
Journal:  Mol Psychiatry       Date:  2016-09-20       Impact factor: 15.992

10.  A homozygous loss-of-function mutation in PDE2A associated to early-onset hereditary chorea.

Authors:  Vincenzo Salpietro; Belen Perez-Dueñas; Kosuke Nakashima; Victoria San Antonio-Arce; Andreea Manole; Stephanie Efthymiou; Jana Vandrovcova; Conceicao Bettencourt; Niccolò E Mencacci; Christine Klein; Michy P Kelly; Ceri H Davies; Haruhide Kimura; Alfons Macaya; Henry Houlden
Journal:  Mov Disord       Date:  2018-02-02       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.